Lupin Receives EIR from U.S. FDA for its Somerset Manufacturing Facility - Lupin | Press Release - lupin.com
Lupin's Somerset Manufacturing Facility has received an Establishment Inspection Report (EIR) from the U.S. FDA, indicating compliance with cGMP standards.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 21, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. All pharmaceutical manufacturers operating under FDA regulations, particularly those involved in cGMP compliance. should confirm how it applies to their specific situation before acting. There is a time constraint attached: N/A. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Receipt of EIR signifies that the facility meets FDA's current good manufacturing practices.
Who it affects
All pharmaceutical manufacturers operating under FDA regulations, particularly those involved in cGMP compliance.
What you must do
Review and ensure ongoing compliance with cGMP standards as per FDA guidelines.
Deadline
N/A
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Guidance: Compounding Animal Drugs from Bulk Drug Substances: Compounding under CGMP in Federally-Registered Facilities
- FDA to require diversity plan for clinical trials - nature.com
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Second Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- FDA Issues Final Rule Clarifying Evidence of Off-Lab... - Dechert
- Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act